Novel serum albumin binding fusion proteins
By modifying the serum albumin-binding protein domain, the fusion protein maintains stability at high temperatures and remains stable in serum for a long time, solving the problems of slow binding speed and insufficient stability of existing fusion proteins at high temperatures, and expanding its applications in medicine.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NAVIGO PROTEINS GMBH
- Filing Date
- 2024-12-11
- Publication Date
- 2026-06-02
AI Technical Summary
Existing fusion proteins bind slowly to serum albumin under high temperature conditions and are unstable in function after incubation in serum, making it difficult to meet the needs of radiolabeling and medical applications.
A novel fusion protein containing a specific serum albumin-binding protein domain was developed. Through amino acid substitution modification, it was made stable at high temperatures and maintained its function in serum for a long time. The affinity for binding human and mouse serum albumin reached the double-digit nanomolar range.
The fusion protein has achieved high-temperature stability and long-term stability in serum, broadening its application potential in the diagnosis and treatment of diseases such as cancer, and is particularly suitable for targeted and radiotherapy of tumor cells.
Smart Images
Figure CN122138972A_ABST